University Of Pittsburgh
- Country
 - 🇺🇸United States
 
- Ownership
 - Private
 
- Established
 - 1787-02-28
 
- Employees
 - 10K
 
- Market Cap
 - -
 
- Website
 - http://www.pitt.edu
 
Clinical Trials
1.4k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1037 trials with phase data)• Click on a phase to view related trials
Circulating Tumor DNA in High Risk Localized Prostate Cancer
- Conditions
 - Prostate Cancer
 
- First Posted Date
 - 2025-10-29
 
- Last Posted Date
 - 2025-10-29
 
- Lead Sponsor
 - University of Pittsburgh
 
- Target Recruit Count
 - 24
 
- Registration Number
 - NCT07222436
 
- Locations
 - 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
 
Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application
- Conditions
 - CancerSolid Tumor CancerChemotherapy
 
- First Posted Date
 - 2025-10-20
 
- Last Posted Date
 - 2025-10-20
 
- Lead Sponsor
 - University of Pittsburgh
 
- Target Recruit Count
 - 50
 
- Registration Number
 - NCT07218874
 
- Locations
 - 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
 
Effects of Operational Naps on Blood Pressure and Performance Among Night Shift Workers
- Conditions
 - Shift Work
 
- First Posted Date
 - 2025-10-16
 
- Last Posted Date
 - 2025-10-16
 
- Lead Sponsor
 - University of Pittsburgh
 
- Target Recruit Count
 - 130
 
- Registration Number
 - NCT07217769
 
- Locations
 - 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
 
Evaluating the Effectiveness of the Health App Reccommendation Tool
- Conditions
 - Alzheimers Disease Related Dementias
 
- First Posted Date
 - 2025-10-15
 
- Last Posted Date
 - 2025-10-15
 
- Lead Sponsor
 - University of Pittsburgh
 
- Target Recruit Count
 - 15
 
- Registration Number
 - NCT07216716
 
- Locations
 - 🇺🇸
Univeristy of Pittsburgh, Pittsburgh, Pennsylvania, United States
 
Pilot-Testing Strategies to Improve Outcomes for Youth With Type 2 Diabetes by Addressing Health-Related Social Needs
- Conditions
 - Diabetes in AdolescenceType 2 DiabetesSocial Needs
 
- First Posted Date
 - 2025-10-14
 
- Last Posted Date
 - 2025-10-14
 
- Lead Sponsor
 - University of Pittsburgh
 
- Target Recruit Count
 - 104
 
- Registration Number
 - NCT07216118
 
- Locations
 - 🇺🇸
UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
 
- Prev
 - 1
 - 2
 - 3
 - 4
 - 5
 - 276
 - Next
 
News
Medicus Pharma and HelixNano Partner to Develop Needle-Free, Heat-Stable mRNA Vaccines
Medicus Pharma and HelixNano have signed a non-binding memorandum of understanding to develop thermostable mRNA vaccines that eliminate cold-chain storage requirements.
Sucralose Artificial Sweetener Reduces Cancer Immunotherapy Effectiveness Through Gut Microbiome Disruption
University of Pittsburgh researchers found that sucralose consumption is associated with worse overall response and progression-free survival in cancer patients receiving anti-PD-1 immunotherapy.
Researchers Unveil New Strategies to Harness Tumor Microenvironment for Enhanced Cancer Immunotherapy
Researchers at the 2025 ASCO Annual Meeting revealed how the tumor microenvironment's complex balance of pro-tumor and anti-tumor immune forces can be manipulated to improve immunotherapy responses.
FDA Approves IDE for ECM Therapeutics' Novel Hydrogel Treatment for Anorectal Fistulas
ECM Therapeutics has received FDA Investigational Device Exemption approval for ECMT-100, a regenerative hydrogel derived from extracellular matrix designed to treat anorectal fistulas non-surgically.
Magnetic Silk Microparticles: A Breakthrough for Targeted Drug Delivery
University of Pittsburgh researchers have developed silk iron microparticles (SIMPs) that can be magnetically guided through the body to deliver treatments directly to disease sites like tumors or aneurysms.
American Heart Association Awards $1M to Study GLP-1 Medications' Impact on Cardiovascular Risk
The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.
Elahere Demonstrates Significant Survival Benefit in Phase III MIRASOL Trial for Platinum-Resistant Ovarian Cancer
AbbVie's final analysis of the phase III MIRASOL trial confirms Elahere (mirvetuximab soravtansine) provides superior efficacy compared to chemotherapy in folate receptor alpha-positive platinum-resistant ovarian cancer patients.
Novel Spinal Cord Stimulation Shows Promise in Treating Spinal Muscular Atrophy
A groundbreaking pilot study demonstrates that spinal cord implants delivering low-level electrical stimulation helped three adults with spinal muscular atrophy regain muscle function and mobility.
Experimental Nasal Swab Distinguishes Asthma Subtypes in Novel Diagnostic Approach
A novel nasal swab shows promise in differentiating between T2-high and T2-low asthma, offering a more precise diagnosis compared to current methods.
Novel Compound SYM2081 Shows Promise in Treating Inflammatory Skin Conditions Like Rosacea
Researchers have identified a novel compound, SYM2081, that targets mast cells to reduce inflammation in skin conditions like rosacea.
